Cipla gains on launching therapy for Knee Osteoarthritis `Ciplostem`
Cipla is currently trading at Rs 1511.25, up by 3.15 points or 0.21% from its previous closing of Rs 1508.10 on the BSE.
The scrip opened at Rs 1502.40 and has touched a high and low of Rs 1511.25 and Rs 1502.40 respectively. So far 6335 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52-week high of Rs 1672.20 on 23-Oct-2025 and a 52-week low of Rs 1310.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 1536.20 and Rs 1495.95 respectively. The current market cap of the company is Rs 121949.22 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.79% and 16.00% respectively.
Cipla has partnered with Stempeutics Research to launch Ciplostem, a therapy for Knee Osteoarthritis, approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla's entry into Orthobiologic medicine.
Through this launch, Cipla and Stempeutics reaffirm their collective focus on science- driven progress in chronic disease management, offering a next-generation joint preservation therapy aimed at improving patients’ everyday lives.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
